VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer

Abstract

Background VEGF/VEGFR2 pathway is the central therapeutic target in anti-angiogenic treatment in multiple cancers. However, little work has been carried out concerning the pro-malignancy functions of VEGFR2 that are independent of its pro-angiogenesis effects in gastric cancer. Here, we demonstrated that VEGFR2 up-regulation in gastric cancer tissues was a prognostic marker for poor disease-free survival and overall survival of gastric cancer patients. Methods Immunohistochemistry was used to detect VEGFR2 and VTN expressions in specimens. Kaplan–Meier curves were constructed for survival analysis. Stably knockdown cell lines and overexpression cell lines were constructed by small interfering RNA and plasmids transfection. Real-time PCR and Western blot were used to confirm the expressions of target genes at both RNA and protein levels. Cell proliferation was measured by using Cell Counting Kit-8 and xenograft models. Microarray and bioinformatic analysis were also performed to identify the relationship between Vitronectin (VTN) and VEGFR2. Results When overexpressed in gastric cancer cells, VEGFR2 increased cellular proliferation and invasion in vitro and tumor formation in xenograft models. By using integrating microarray and bioinformatic analysis, we identifiedVTN as a downstream of VEGFR2 pathway. In gain- and loss-of function analysis in gastric cancer cells, VTN was further verified in consistent with VEGFR2 in expression levels and in regulating cell growth and motility in vitro and in vivo . Moreover, in gastric cancer samples, VTN was as also revealed as a poor prognostic factor. Conclusions Our present findings defined a novel activity for VEGFR2 in promoting tumorogenicity, motility and indicating a poor survival in gastric cancer beyond its known pro-angiogenic effects. Implications Our present findings defined a novel activity for VEGFR2 in promoting tumorogenicity, motility and indicating a poor survival in gastric cancer beyond its known pro-angiogenic effects, which may provide a new and valuable target for design of therapies for intervention and a new cognitive perspective for the anti-angiogenesis therapies. Electronic supplementary material The online version of this article (10.1186/s12885-019-5322-0) contains supplementary material, which is available to authorized users.

Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway

“…First, we found that VEGFR2 mRNA and protein expression were remarkably increased in esophageal cancer samples compared with associated non-tumor tissues. The finding was in agreement with the results reported in several human cancers [7,30]. Also, our study confirmed that high VEGFR2 expression was associated with later TNM stage, which might suggest that VEGFR2 was essential for ESCC progression.…”

Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines

“…In epithelial tumor cells, the binding of VEGFA to VEGFR2 sustains autocrine loop affecting cell growth and migration. Ram binds the receptor about eight times more effectively than VEGFA 31 , thus targeting not only the neo-angiogenesis in endothelial cells 6 but also the growth and motility of tumor cells [10][11][12][13] . Although the effects of Ram as an anti-angiogenic drug are now well documented, little is known about its role in inhibiting the growth and motility of gastric cancer cells both as single agent and in combination with chemotherapeutic drugs such as PTX.…”

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know

“…In the case of the VEGFR2 gene, which encodes a receptor that responds to the VEGF signal and regulates endothelial migration and proliferation [ 111 ], rs1870377 is reported to increase the affinity and activity of VEGF-A on VEGFR2 with the result of promoting angiogenesis, as reported in nonsmall cell lung cancer tissues [ 112 ]. Moreover, VEGFR2 can boost cancer proliferation and metastasis independently of proangiogenic stimuli [ 113 ]. Although these data are intriguing, they do not provide a biological explanation about how these polymorphisms and anti-PD-1/PD-L1 antibodies can work together in determining HPD.…”